PSMA Biology Explained: Why PSMA Isn't the Answer for All Prostate Cancers

PSMA PET has transformed prostate cancer imaging since 2020. But the technology has limits that aren't well-communicated to patients. About 5–10% of prostate cancers are PSMA-low or PSMA-negative, and these tend to be the more aggressive cases that need treatment most urgently. Understanding why — and knowing when to add FDG PET or other workup — is the difference between informed treatment decisions and over-reliance on a single test.

This article unpacks the biology of PSMA expression, the clinical scenarios where it falls short, and what to do when PSMA is unhelpful.

What PSMA Is (Prostate Membrane Antigen)

Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein encoded by the FOLH1 gene. Despite the name, PSMA is not exclusively expressed in the prostate — small amounts appear in salivary glands, kidneys, small bowel, and brain. But on prostate cancer cells, PSMA expression is upregulated 100–1000-fold over normal tissue.

This dramatic differential is what makes PSMA an exceptional imaging target. Tracers (Ga-68 PSMA, F-18 DCFPyL, F-18 PSMA-1007) bind to the extracellular domain of PSMA and accumulate on cancer cells in proportion to PSMA expression density.

PSMA Expression by Prostate Cancer Subtype

PSMA expression is not uniform across all prostate cancers:

Subtype	PSMA expression	Imaging sensitivity
Acinar adenocarcinoma (most common, 95%+)	High	Excellent
Ductal adenocarcinoma	Variable	Variable
Treatment-induced neuroendocrine prostate cancer (NEPC)	Low to absent	Poor
De novo small cell prostate cancer	Very low	Poor
Castration-resistant aggressive variant	Variable	Variable

The biology: PSMA expression is tied to androgen receptor signaling. When the cancer is hormone-sensitive (driven by androgens), AR signaling is active, PSMA is expressed, and the cancer is imageable. When the cancer becomes castration-resistant and dedifferentiates (often pushed by long-term androgen deprivation therapy), AR signaling shuts off, the cancer adopts a neuroendocrine phenotype, and PSMA expression drops.

The clinical paradox: PSMA imaging works best for cancers that are still hormone-sensitive and least well for the aggressive, treatment-resistant cancers that need to be detected most.

Neuroendocrine Prostate Cancer: PSMA-Negative

Treatment-induced neuroendocrine prostate cancer (NEPC) is an emerging clinical problem. Patients receiving prolonged androgen deprivation therapy (with or without anti-androgens like abiraterone and enzalutamide) can develop NEPC over time. The cancer:

• Loses prostate-specific antigen (PSA) production
• Loses PSMA expression
• Gains neuroendocrine markers (synaptophysin, chromogranin A)
• Becomes glucose-metabolism-dependent (FDG-avid)
• Has small cell-like aggressive behavior

The patient pattern: a long-treated prostate cancer patient whose PSA stops rising despite clinical progression — bone pain, weight loss, new metastases on bone scan or CT. PSMA PET in this scenario can be falsely reassuring (low or no uptake despite progressive disease). FDG PET reveals the active disease.

NEPC incidence in advanced castration-resistant patients: ~5–17% depending on the population studied. Higher in patients receiving long-term, intensive androgen suppression.

Why PSA Low + PSMA Negative Happens

Two distinct scenarios:

Treated low-volume disease: A patient successfully treated with surgery or radiation has eradicated PSMA-expressing cells. PSA is low because there is little cancer. PSMA PET is negative because there is no PSMA-expressing tissue to image.

Neuroendocrine transformation: A patient on long-term hormone treatment has cancer cells that have switched off PSMA but switched on glucose metabolism. PSA is low because the cells no longer make PSA. PSMA PET is negative because PSMA is gone. Cancer is present and active but imageable only with FDG.

Distinguishing the two requires:
- Clinical context (PSA trajectory, bone pain, symptoms)
- FDG PET (reveals NEPC if present)
- Biopsy of any suspicious lesion (neuroendocrine markers on pathology)

Combining PSMA with FDG When Aggressive

For patients with aggressive castration-resistant prostate cancer (CRPC) and concern for NEPC, a dual-tracer approach is sometimes used:

1. PSMA PET: identifies any remaining adenocarcinoma component
2. FDG PET (separate scan, often within 2 weeks): identifies neuroendocrine-differentiated disease

Patients with PSMA-positive AND FDG-positive disease have heterogeneous cancer requiring combined treatment. Patients with predominantly FDG-positive but PSMA-negative disease are likely NEPC and may benefit from platinum-based chemotherapy rather than PSMA-directed therapy.

The dual-tracer cost: roughly 1.7–1.8× the cost of a single scan ($8,000–13,000 US; ¥18,000–28,000 China).

For dual-tracer imaging in aggressive prostate cancer, our team can help.

PSMA in Other Cancers (RCC, Glioma) Off-Label

PSMA was thought to be prostate-exclusive at first. Subsequent research showed PSMA expression in tumor neovasculature of other cancers:

• Renal cell carcinoma: PSMA expression in tumor blood vessels; emerging imaging application
• Glioblastoma: PSMA expression in tumor vasculature
• Hepatocellular carcinoma: variable expression
• Other solid tumors with neovasculature

These are off-label and research applications in 2026. For approved clinical use, PSMA imaging remains a prostate cancer tool.

Theranostics: PSMA for Treatment, Not Just Imaging

PSMA-targeted therapy (Lu-177 PSMA-617, marketed as Pluvicto, FDA-approved 2022) delivers radiation directly to PSMA-expressing tumor cells. Treatment cycle:

1. PSMA PET imaging confirms PSMA expression and disease extent
2. Lu-177 PSMA infusion every 6 weeks
3. Typical 4–6 cycles total
4. Repeat PSMA PET after every 2–3 cycles for response assessment

Treatment selection requires PSMA-positive disease — exactly why a careful pre-treatment PSMA PET is important. Patients with PSMA-low or PSMA-negative disease will not benefit and should not receive Lu-177 PSMA.

Cost:
- US: $25,000–35,000 per Pluvicto cycle
- China: ¥80,000–150,000 per cycle ($11,400–21,400)

China-based Lu-177 PSMA treatment has become an option for self-pay international patients. Top centers: Fudan SCC Shanghai, Sun Yat-sen Cancer Center, PUMC Beijing.

Self-Pay PSMA Imaging in China

International patients accessing PSMA PET in mainland China:

• PUMC Beijing: ¥10,000–13,000; Ga-68 PSMA-11 standard
• Fudan SCC Shanghai: ¥10,000–15,000; both Ga-68 and F-18 PSMA available; theranostic program
• Sun Yat-sen Cancer Center Guangzhou: ¥10,000–13,000; integrated urology multidisciplinary
• HKU-Shenzhen Hospital: ¥9,000–12,000; F-18 PSMA; easy from Hong Kong
• Ruijin Shanghai: ¥10,000–14,000; Ga-68 PSMA standard

Typical pathway: pre-arrival video consult, arrival day 1 with urology consultation, scan day 2, results day 3, departure day 4. For patients pursuing Lu-177 therapy, a longer stay (1–2 weeks per cycle) may be necessary.

Frequently Asked Questions

My PSMA PET was negative but my PSA is rising. What now?
Several possibilities: early biochemical recurrence below PSMA detection threshold (especially at PSA <0.5), neuroendocrine transformation (consider FDG PET), or false-negative scan. Discuss next steps with your urologist — often repeat PSMA at higher PSA or add FDG PET.

Can a young, low-volume prostate cancer be NEPC?
Rarely. De novo small cell or neuroendocrine prostate cancer is uncommon (<5% of new prostate cancer diagnoses). Treatment-induced NEPC occurs after years of treatment.

Does PSMA imaging affect my treatment plan?
Significantly. PSMA-positive metastatic disease → consider Lu-177 PSMA therapy. PSMA-positive limited disease → consider focal radiation. PSMA-negative aggressive disease → consider platinum-based chemotherapy and biopsy for histologic confirmation.

Are there PSMA-expressing benign tissues that cause false positives?
Yes. Salivary glands, kidneys, lacrimal glands, ganglia, and some inflammatory lesions can show PSMA uptake. Experienced readers recognize these patterns and don't mistake them for cancer.

Will the PSA still be useful if PSMA imaging is so much better?
Yes. PSA is a sensitive marker of any prostate epithelium activity. PSA + PSMA imaging together is more powerful than either alone. PSA is the trigger; PSMA shows where the disease is.

Should I get PSMA PET even if I have low-risk localized prostate cancer?
NCCN and EAU guidelines reserve PSMA for unfavorable intermediate-risk, high-risk, very high-risk, or biochemically recurrent disease. Low-risk disease typically doesn't need staging PSMA.

Need Help Booking?

SinoCareLink can pre-book PSMA PET-CT (Ga-68 or F-18) or dual PSMA + FDG imaging at a top Chinese hospital, coordinate Lu-177 PSMA theranostic treatment if indicated, translate reports into English, and arrange airport pickup. Contact us for a free consultation.